Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 4,007

The DOI matches its Crossref record; 382 of the 382 references it cites were found in a registry or an index.

Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments

Open access
Grauer, Oliver M., Wesseling, Pieter, Adema, Gosse J.·2009·Brain Pathology

Abstract

Despite aggressive multimodal treatment approaches, the prognosis for patients with diffuse gliomas remains disappointing. Glioma cells often extensively infiltrate in the surrounding brain parenchyma, a phenomenon that helps them to escape surgical removal, radiation exposure and chemotherapy. Moreover, conventional therapy is often associated with considerable local and systemic side effects. Therefore, the development of novel therapeutic approaches is essential to improve the outcome of these patients. Immunotherapy offers the opportunity to specifically target residual radio—and chemoresistant tumor cells without damaging healthy neighboring brain tissue. Significant progress has been made in recent years both in understanding the mechanisms of immune regulation in the central nervous system (CNS) as well as tumor‐induced and host‐mediated immunosuppression elicited by gliomas. In this review, after discussing the special requirements needed for the initiation and control of immune responses in the CNS, we focus on immunological phenomena observed in glioma patients, discuss different immunological approaches to attack glioma‐associated target structures and touch on further strategies to improve the efficacy of immunotherapy of gliomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1750-3639.2009.00315.x

Cites

382 of 382 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 382 references

Research works printed but not linked: 28

  1. 10.1111/j.1365-2990.1997.tb01315.x · doi:10.1111/j.1365-2990.1997.tb01315.x · Paper page
  2. 10.1007/BF02893856 · doi:10.1007/bf02893856
  3. Blancher A, 1993, Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin‐2 and LAK cells, Eur Cytokine Netw, 4, 331
  4. Buccoliero AM, 2006, Inducible cyclooxygenase (COX‐2) in glioblastoma–clinical and immunohistochemical (COX‐2‐VEGF) correlations, Clin Neuropathol, 25, 59
  5. Castelli MG, 1989, Prostaglandin and thromboxane synthesis by human intracranial tumors, Cancer Res, 49, 1505
  6. Dunn GP, 2007, Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma, Cancer Immun, 7, 12
  7. 10.1007/s11060-007-9442-z · doi:10.1007/s11060-007-9442-z
  8. 10.1016/0008-8749(92)90096-8 · doi:10.1016/0008-8749(92)90096-8
  9. 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J · doi:10.1002/1521-4141(200211)32:11<3235::aid-immu3235>3.0.co;2-j
  10. 10.1002/(SICI)1097-0215(19991210)83:6<760::AID-IJC11>3.0.CO;2-R · doi:10.1002/(sici)1097-0215(19991210)83:6<760::aid-ijc11>3.0.co;2-r
  11. 10.1080/01616412.1990.11739955 · doi:10.1080/01616412.1990.11739955
  12. Insug O, 2002, A dendritic cell vaccine induces protective immunity to intracranial growth of glioma, Anticancer Res, 22, 613
  13. Jacobs SK, 1986, Interleukin‐2 or autologous lymphokine‐activated killer cell treatment of malignant glioma: phase I trial, Cancer Res, 46, 2101
  14. 10.1002/cncr.11122 · doi:10.1002/cncr.11122
  15. Kim JA, 2001, Divergent effects of 4‐1BB antibodies on antitumor immunity and on tumor‐reactive T‐cell generation, Cancer Res, 61, 2031
  16. 10.1007/BF00195603 · doi:10.1007/bf00195603
  17. 10.1517/14712598.4.7.1115 · doi:10.1517/14712598.4.7.1115
  18. 10.1007/s002620050405 · doi:10.1007/s002620050405
  19. 10.2739/kurumemedj.44.43 · doi:10.2739/kurumemedj.44.43
  20. 10.1034/j.1399-0039.2002.600406.x · doi:10.1034/j.1399-0039.2002.600406.x
  21. 10.1007/BF00205425 · doi:10.1007/bf00205425
  22. 10.1007/BF02700016 · doi:10.1007/bf02700016
  23. 10.1093/intimm/11.8.1337 · doi:10.1093/intimm/11.8.1337
  24. 10.1007/s00262-002-0270-x · doi:10.1007/s00262-002-0270-x
  25. 10.1007/s00262-008-0461-1 · doi:10.1007/s00262-008-0461-1
  26. Safdari H, 1979, Histological correlations with survival in malignant gliomas, Acta Neurochir Suppl (Wien), 28, 485
  27. 10.1158/0008-5472.CAN-05-2967 · doi:10.1158/0008-5472.can-05-2967
  28. 10.1023/A:1006456421177 · doi:10.1023/a:1006456421177

Cited by

See all 4,007

Metadata

Authors
Grauer, O. M., Wesseling, P., & Adema, G. J.
Venue
Brain Pathology
Publisher
Wiley
Published
2009-09-04
Volume
19
Issue
4
Pages
674-693
ISSN
  • 1015-6305 (ISSN-L)
  • 1750-3639
OpenAlex
W2165871546
Cited by
4,007
References
382
FWCI
23.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments. https://app.cochat.ai/papers/10.1111/j.1750-3639.2009.00315.x
The paper
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009). Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments. Brain Pathology. https://doi.org/10.1111/j.1750-3639.2009.00315.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.